Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023

SELL
$67.18 - $84.11 $11,219 - $14,046
-167 Reduced 1.46%
11,269 $905,000
Q3 2022

Nov 03, 2022

SELL
$66.18 - $82.86 $727 - $911
-11 Reduced 0.1%
11,436 $763,000
Q2 2022

Aug 05, 2022

BUY
$66.18 - $83.18 $59,959 - $75,361
906 Added 8.6%
11,447 $870,000
Q1 2022

May 10, 2022

BUY
$66.02 - $79.71 $59,418 - $71,739
900 Added 9.34%
10,541 $837,000
Q4 2021

Feb 04, 2022

BUY
$63.34 - $74.11 $16,785 - $19,639
265 Added 2.83%
9,641 $708,000
Q3 2021

Oct 28, 2021

SELL
$68.67 - $84.02 $25,682 - $31,423
-374 Reduced 3.84%
9,376 $645,000
Q2 2021

Aug 03, 2021

BUY
$79.87 - $87.53 $778,732 - $853,417
9,750 New
9,750 $820,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $13.5B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Amg National Trust Bank Portfolio

Follow Amg National Trust Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amg National Trust Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amg National Trust Bank with notifications on news.